Pediatric clinical trials play a major role in modern healthcare, as pediatric clinical trials are the only criteria to launch new drugs in market for various indications that affect pediatric population. Clinical trials in children are essential to develop age-specific, empirically-verified therapies and interventions to determine and improve the best medical treatment available.
There is significant product pipeline under clinical stage of development due to unmet medical needs for pediatric patient population. A pediatric clinical trial could assist in determining the ideal dosage of a medication or vaccine for a child, or it could concentrate on creating an easier-to-swallow liquid formulation. Clinical trials involving children aid in the development of child-safe and -effective medications and vaccinations. A pediatric clinical trial could help develop the correct dose of a medicine or vaccine for a child, or it could focus on development of a liquid formulation that is easier to swallow. Participation from children in clinical trials helps develop medicines and vaccines that are safe and effective for children.
Market Dynamics
Increasing demand for new vaccines and other biologic products to prevent various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis is expected to drive the market growth. For instance, according to the International Diabetes Federation’s (IDF) Diabetes Atlas 2020, around 463 million patients were suffering from diabetes worldwide in 2019. Of this, one million people (children and adolescents below 20 years of age) were suffering from type 1 diabetes.
Key features of the study:
- This report provides in-depth analysis of the global pediatric clinical trials market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global pediatric clinical trials market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global pediatric clinical trials market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric clinical trials market
Detailed Segmentation:
- Global Pediatric Clinical Trials Market, By Clinical Trial Phase :
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Global Pediatric Clinical Trials Market, By Study Design:
- Treatment Studies
- Observational Studies
- Global Pediatric Clinical Trials Market, By Medical Condition:
- Neuropsychiatric Conditions
- Infectious Diseases,
- Maternal and Perinatal Conditions,
- Respiratory Diseases,
- Cardiovascular Diseases
- Cancer
- Digestive
- Others
- Global Pediatric Clinical Trials Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Syneos Health Inc
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- IQVIA Holdings, Inc.,
- Charles River Laboratories International Inc.
- Covance Inc.,
- ICON plc,
- Pharmaceutical Product Development, LLC,
- Genentech (F. Hoffmann-La Roche AG),
- Pfizer, Inc.,
- Bristol - Myers Squibb,
- GlaxoSmithKline plc.,
- Sanofi S.A.,
- Novartis AG,
- Johnson & Johnson,
- Merck & Co., Inc.,
- Takeda Pharmaceutical Company Limited,
- Vertex Pharmaceuticals Inc
“*” marked represents similar segmentation in other categories in the respective section.
